- Work address:
- Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
-
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
E-pub date: 20 May 2021Journal name: Journal of Clinical Oncology
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.
E-pub date: 31 Mar 2021Journal name: Nat Commun
OC-0451: Radiation response of breast carcinoma cells with enhanced metastatic capacities
E-pub date: 1 Nov 2020Journal name: Radiotherapy and Oncology